Amplicon sequencing revealed that the bla KPC-2 gene was in all cases embedded in a Tn4401-like transposon. Published papers have reported that Tn4401 has been found on IncN and IncFII k plasmids (pKpQIL-IT, S9, S12, S15, pKPN101-IT); therefore, for the detection of these plasmids, we used the following primers: S9-F, 5
′ -GCATTGACCTTGGCATCTTC-3 ′ ; S9-R, 5 ′ -GTGATTTACACCAC CACCTCATCA-3 ′ ; S12-F, 5 ′ -CGGACGGTTGATCAGAATCGGATG-3 ′ ; S12-R, 5
′ -ATTGCTGCTGTAGGGGCTGTCATTCT-3 ′ ; S15-F, 5 ′ -GGGGAT CGGTTTTCGCCAGCA-3 ′ ; S15-R, 5 ′ -GCTTTACCGAGGGAGAATGGCTA CTG-3 ′ ; pSLMT-F, 5 ′ -GCATTGACCTTGGCATCTTC-3 ′ ; pSLMT-R, 5
′ -CTAATAAACTGGTGCTCGGACAGA-3 ′ ; pNYC-F, 5 ′ -GCATCAAACGG AAGCAAAAG-3 ′ ; pNYC-R, 5 ′ -CTTAGCAAATGTGGTGAACG-3 ′ ; pKpQIL-IT-F, 5
′ -GGTTATTGGGTGAGGTAAGCATTAGGCG-3 ′ ; and pKpQIL-IT-R, 5 ′ -GAGTGAGCGAGGAAGCACCAGGG-3 ′ -designed on the basis of published sequences and specific for each plasmid (GenBank accession numbers FJ223607.1, FJ223605.1, FJ223606.1, HQ589350.1, EU176011.1 and GU595196.1, respectively). 10 In all strains amplicon sequence analysis (1071 bp) showed that plasmid sequences matched the pKpQIL-IT plasmid, circulating in Italy and already detected in a strain of K. pneumoniae ST258 background. 6 Furthermore, as regards the coexistence of methylase armA in KPC-producing K. pneumoniae, already found to be associated on pETKp90 and pETKp50 plasmids and on the same pKP048 plasmid, 4, 5 Southern blot experiments on genomic and plasmid DNAs with the bla KPC , armA and pKpQIL-IT probes obtained by PCR fragments were performed. A hybridization signal on the same fragment of 97 kb in all strains was found, suggesting that these genes are located on the same element. Further studies are in progress in our laboratory in order to identify the element carrying the armA gene.
In conclusion, our findings suggest that KPC-2-and ArmAproducing K. pneumoniae strains are emerging in an ST101 background. These clones are extensively resistant, also due to lateral gene transfer, rendering all families of drugs useless and requiring only antibiotic combinations (G. Ceccarelli, M. Falcone, A. Giordano, M. L. Mezzatesta, C. Caio, S. Stefani and M. Venditti, unpublished results). Furthermore, the diffusion of these epidemic clones requires the activation of infection control procedures. Keywords: antimicrobial resistance, Enterobacteriaceae, Gram-negative Sir, Bacteria of the genus Providencia are Gram-negative opportunistic pathogens that have been isolated from a wide variety of environments, including human stool samples. They comprise part of the natural human gut flora but may also cause infections, including travellers' diarrhoea.
1 They are also responsible for urinary tract and other nosocomial infections in humans. 2 The New Delhi metallo-b-lactamase (NDM-1) is the most recently discovered transferable molecular class B metallob-lactamase. The gene encoding this enzyme was located on a 178 kb plasmid belonging to incompatibility group A/C in a Providencia stuartii clinical isolate. 3 However, it has been described in different plasmid types (IncA/C, IncF, IncL/M, IncN or untypeable) and is also chromosomally integrated. 4 This work describes four Providencia rettgeri clinical isolates obtained from patients with urinary tract infection in the intensive care unit (ICU) of the University Hospital of Monterrey, Mexico, between January and June 2012 ( Table 1 ). The P. rettgeri isolates were identified using the API 20E galleries (bioMé rieux, Durham, NC, USA) and confirmed by Sensititre (TEK Diagnostic Systems Inc., Cleveland, OH, USA). In addition, the 16S rRNA gene was characterized by using primers previously described. 5 A possible epidemiological link between the patients was a surgical resident involved in the care of the four patients while in the ICU. None of the patients had evidence of infection prior to being transferred to the ICU; the average time to positive urine cultures for P. rettgeri was 29 days (range 12 -68 days).
MICs were determined by broth microdilution following CLSI recommendations 6 and the phenotypic screening to determine the production of a carbapenemase enzyme was carried out using a double-disc synergy test (meropenem, imipenem and EDTA). 6 The isolates were screened using PCR for genes encoding a range of carbapenemase enzymes, including KPC, GES, IMP, SIM, GIM, SPM, VIM and NDM. 7 Genotyping was performed using PFGE and the results were analysed following the guidelines of Tenover et al. 8 using GelCompar II (Applied Math, Kortrijk, Belgium). The plasmid profile was analysed using ioninterchange columns (Qiagen, Valencia, CA, USA); subsequently, a Southern hybridization was carried out with a non-radioactive probe for the NDM-1 gene. Mating and transformation experiments and identification of plasmid incompatibility groups by PCR replicon typing were undertaken as described previously. 9, 10 The genotyping analysis of the four P. rettgeri isolates showed one clonal group (data not shown). All isolates were susceptible to tigecycline (1 mg/L), but resistant to imipenem, meropenem, piperacillin, ceftazidime, cefotaxime, ciprofloxacin and colistin ( Table 1 ). The isolates were positive for carbapenemase activity and the PCR assays and sequencing demonstrated the presence of the gene encoding NDM-1. According to the Southern hybridization (data not shown) and PCR replicon typing results obtained with the transconjugants and recombinants, the NDM-1 gene was identified on a 310 kb IncK plasmid (Table 1) . However, the mating and the transformation experiments showed the respective transconjugant (310 kb and 160 kb) and transformant (310 kb and 50 kb) with two different plasmids harboured in the clinical isolates (Table 1) . Similar results have been recently described suggesting that a helper plasmid is necessary for the mobilization of the plasmid-borne NDM-1. 11 In this work, the 160 kb plasmid could be playing the role of helper. This is the first known report of an NDM-1-producing P. rettgeri in Mexico. This finding points to the need to enforce the molecular epidemiological surveillance of these pathogens and enzymes in order to prevent their dissemination among hospitals as well as to other bacterial genera. 1 that avermectins, including ivermectin, selamectin and moxidectin, are bactericidal against several isolates of Mycobacterium tuberculosis, including multidrug-resistant and extensively drug-resistant clinical isolates. Ivermectin is a semi-synthetic avermectin (macrocyclic lactone) produced by the soil actinomycete Streptomyces avermitilis.
2 It has been successfully used to treat parasitic infections, including onchocerciasis, strongyloidiasis, ascariasis, cutaneous larva migrans, filariases, gnathostomiasis and trichuriasis, as well as pediculosis. 3, 4 Apart from the study by Lim et al., 1 only one study has shown the in vitro antimicrobial activity of ivermectin against Chlamydia trachomatis using a cellular model. 5 Here, we tested an additional set of 13 M. tuberculosis complex isolates from France as no European isolate had been incorporated into the previous study. 1 This collection consisted of 10 M. tuberculosis clinical isolates and three reference strains (M. tuberculosis H37Rv, Mycobacterium canettii CIP 140010059 and Mycobacterium bovis BCG Pasteur 1173P2). Ivermectin concentrations were chosen to match those used by Lim et al. 1 Briefly, mycobacteria were cultured at 378C in 7H9 Middlebrook medium supplemented with 10% (v/v) oleic acid/albumin/dextrose/catalase (OADC) (Becton Dickinson, Sparks, MD, USA) and 0.5% (v/v) glycerol to mid-log phase (optical density of 0.5 at 600 nm). MICs were determined using an agar dilution method after dilution of ivermectin in Middlebrook 7H10 medium supplemented with OADC. Sterile 6-well tissue culture plates (Dominique Dutscher,
